Propanc Biopharma (PPCB) Retained Earnings (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Retained Earnings of $1.3 million for Q4 2025, down 10.98% year-over-year from $1.5 million in Q4 2024, and down 99.07% quarter-over-quarter from $143.5 million in Q3 2025.
Propanc Biopharma (PPCB) Retained Earnings (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Retained Earnings for 15 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 10.98% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.3 million (down 10.98% YoY), while the FY2025 annual figure was $138.2 million, up 307.27% from the prior year.
- Retained Earnings declined to $1.3 million in Q4 2025 per PPCB's latest filing, from $143.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $143.5 million in Q3 2025 and bottomed at -$66.7 million in Q2 2024.
- Historically, Retained Earnings has averaged $13.8 million across 5 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 4953.55% — and 2024, when it tumbled 5250.93%.
- Propanc Biopharma's Retained Earnings stood at $1.1 million in 2021, then soared by 4953.55% to $57.7 million in 2022, then plunged by 97.86% to $1.2 million in 2023, then advanced by 20.89% to $1.5 million in 2024, then decreased by 10.98% to $1.3 million in 2025.
- Business Quant data shows PPCB's Retained Earnings at $1.3 million in Q4 2025, $143.5 million in Q3 2025, and $138.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 143.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 143.52 Mn |
| Jun 30, 2025 | 138.24 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 61.13 Mn |
| Jun 30, 2024 | -66.70 Mn |
| Mar 31, 2024 | -66.34 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Sep 30, 2023 | 60.85 Mn |
| Jun 30, 2023 | 1.29 Mn |
| Mar 31, 2023 | -63.88 Mn |
| Dec 31, 2022 | 57.70 Mn |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 56.32 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 1.15 Mn |
| Jun 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | -57.03 Mn |